Loading patent…
AssigneeCLS Therapeutics Limited
InventorsDmitry Dmitrievich Genkin, Viktor Veniaminovich Tets, Georgy Viktorovich Tets
Estimating the term…
A method to treat cancer and other malignant diseases, said method comprising parenterally administering an agent which destroys blood extracellular DNA into the systemic circulation of a cancer patient to slow down cancer growth. The agent is embodied in the form of a DNase enzyme and, more particularly, as a DNase I enzyme. Doses from 50,000-250,000,000 Kunitz units/day are administered for 5-360 days.
A method of treating a cancer by inhibiting growth of a primary tumor and metastasis in a patient in need thereof, wherein said primary tumor and metastasis are accompanied with elevation of blood extracellular DNA level, said method comprising parenterally administering to the patient a DNase enzyme in doses and regiments which provide depolymerization of blood extracellular DNA, wherein the administration of said DNase results in inhibiting growth of the primary tumor and metastasis.
Dependencies are inferred from the claim text.
Drawings are temporarily unavailable. Open the PDF at USPTO
From the US filing history. Foreign family members aren’t listed.
Acting on ester bonds: ribonucleases [RNase]; Deoxyribonucleases [DNase]
Hydrolases: acting on ester bonds , e.g. lipases, ribonucleases
Antineoplastic agents
Endodeoxyribonucleases producing 5'-phosphomonoesters: type I site-specific deoxyribonuclease
Term ended 12 Jan 2026 (estimated)
1. Field of the Invention
The present invention generally relates to a method for treating oncological diseases by administering an agent that destroys extracellular DNA in the blood of a cancer patient.
2. Description of the Background Art
The inventive method is realized as followed:
1. Materials and Methods.
The following agents were used which destroy extracellular blood DNA: bovine pancreatic DNase (Sigma and Samson Med), recombinative human DNase 1 (Dornase alpha; Genetech), Serratia Mercenses extracellular nuclease. The solutions of DNase for administration were made by dissolving of mother solutions of DNase in sterile phosphate buffer just before administration.